Abbreviations |
|
xiii | |
|
|
1 | (2) |
|
|
3 | (26) |
|
|
3 | (7) |
|
2.1.1 Strategic directions in the regulation of medicines and other health technologies |
|
|
3 | (2) |
|
2.1.2 Vaccines and biotherapeutics: recent and planned activities in biological standardization |
|
|
5 | (3) |
|
2.1.3 Blood products and in vitro diagnostics: recent and planned activities in biological standardization |
|
|
8 | (2) |
|
|
10 | (3) |
|
2.2.1 Report from the WHO Blood Regulators Network |
|
|
10 | (2) |
|
2.2.2 Report from the WHO network of collaborating centres on standardization and regulatory evaluation of vaccines |
|
|
12 | (1) |
|
2.2.3 Report from the WHO network of collaborating centres for blood products and in vitro diagnostics |
|
|
13 | (1) |
|
2.3 Feedback from custodian laboratories |
|
|
13 | (3) |
|
2.3.1 Developments and scientific issues highlighted by custodians of WHO biological reference preparations |
|
|
13 | (3) |
|
2.4 Cross-cutting activities of other WHO committees and groups |
|
|
16 | (9) |
|
2.4.1 Update from the WHO Expert Committee on Specifications for Pharmaceutical Preparations |
|
|
16 | (1) |
|
2.4.2 WHO Global Benchmarking Tool |
|
|
17 | (1) |
|
2.4.3 Development of WHO guidelines on good regulatory practices |
|
|
18 | (1) |
|
2.4.4 Snake-bite envenoming |
|
|
19 | (2) |
|
2.4.5 Update from the WHO Product Development for Vaccines Advisory Committee |
|
|
21 | (1) |
|
2.4.6 Pilot WHO prequalification of biosimilar monoclonal antibodies |
|
|
22 | (1) |
|
2.4.7 Model NRA Lot Release Certificate for prequalified vaccines |
|
|
23 | (1) |
|
2.4.8 Planned proficiency testing study of a standardized method for determining total and free saccharide content of Hib liquid combined vaccines |
|
|
24 | (1) |
|
2.4.9 Vaccine prequalification-establishment of the WHO-NNB |
|
|
24 | (1) |
|
|
25 | (4) |
|
2.5.1 Standards for priority pathogens for public health emergencies |
|
|
25 | (2) |
|
2.5.2 International standards and reference preparations - revision of TRS 932 Annex 2 |
|
|
27 | (2) |
|
3 International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological substances |
|
|
29 | (9) |
|
3.1 Biotherapeutics other than blood products |
|
|
29 | (1) |
|
3.1.1 Guidelines on procedures and data requirements for changes to approved biotherapeutic products |
|
|
29 | (1) |
|
3.2 Cellular and gene therapies |
|
|
30 | (1) |
|
3.2.1 Global activities in cell therapy products |
|
|
30 | (1) |
|
|
31 | (5) |
|
3.3.1 WHO IVD prequalification: update report |
|
|
31 | (2) |
|
3.3.2 Human immunodeficiency virus rapid diagnostic tests for professional use and/or self-testing |
|
|
33 | (1) |
|
3.3.3 Establishing stability of in vitro diagnostic medical devices |
|
|
34 | (1) |
|
3.3.4 WHO consultation on the First WHO International Standard for anti-rubella immunoglobulin |
|
|
35 | (1) |
|
3.4 Vaccines and related substances |
|
|
36 | (2) |
|
3.4.1 Guidelines on the quality, safety and efficacy of Ebola vaccines |
|
|
36 | (2) |
|
4 International reference materials - antibiotics |
|
|
38 | (1) |
|
4.1 Proposed new projects and updates-antibiotics |
|
|
38 | (1) |
|
4.1.1 Proposed Third WHO International Standard for erythromycin |
|
|
38 | (1) |
|
5 International reference materials - biotherapeutics other than blood products |
|
|
39 | (5) |
|
5.1 WHO International Standards and Reference Reagents - biotherapeutics other than blood products |
|
|
39 | (5) |
|
5.1.1 Second WHO International Standard for parathyroid hormone 1-34 (recombinant, human) |
|
|
39 | (1) |
|
5.1.2 First WHO International Standard for rituximab |
|
|
40 | (1) |
|
5.1.3 First WHO International Standard for infliximab |
|
|
41 | (3) |
|
6 International reference materials - blood products and related substances |
|
|
44 | (4) |
|
6.1 WHO International Standards and Reference Reagents - blood products and related substances |
|
|
44 | (4) |
|
6.1.1 First WHO Reference Reagent for activated blood coagulation factor X (human) |
|
|
44 | (1) |
|
6.1.2 Second WHO International Standard for activated blood coagulation factor IX (human) |
|
|
45 | (1) |
|
6.1.3 First WHO International Standard for blood coagulation factor XII (plasma, human) via assignment of additional analytes to the current Second WHO International Standard for blood coagulation factor XI (plasma, human) |
|
|
46 | (2) |
|
7 International reference materials - in vitro diagnostics |
|
|
48 | (20) |
|
7.1 WHO International Standards and Reference Reagents - in vitro diagnostics |
|
|
48 | (11) |
|
7.1.1 First WHO Reference Reagent for lupus anti-dsDNA serum |
|
|
48 | (1) |
|
7.1.2 Third WHO International Standard for hepatitis A virus RNA for NAT-based assays |
|
|
49 | (1) |
|
7.1.3 Fourth WHO International Standard for HIV-1 RNA for NAT-based assays |
|
|
50 | (1) |
|
7.1.4 First WHO International Standard for Ebola virus antibodies (plasma, human); and First WHO Reference Panel for Ebola virus antibodies (plasma, human) |
|
|
51 | (1) |
|
7.1.5 First WHO Reference Panel for genomic KRAS codons 12 and 13 mutations |
|
|
52 | (2) |
|
7.1.6 First WHO International Standard for human herpes virus 6B DNA for NAT-based assays |
|
|
54 | (1) |
|
7.1.7 First WHO International Standard for Plasmodium falciparum antigens |
|
|
55 | (1) |
|
7.1.8 First WHO International Standard for anti-cytomegalovirus immunoglobulin G |
|
|
56 | (1) |
|
7.1.9 First WHO International Standard for chikungunya virus RNA for NAT-based assays |
|
|
57 | (1) |
|
7.1.10 First WHO International Standard for Zika virus antibodies (immunoglobulin G and immunoglobulin M) (human) |
|
|
58 | (1) |
|
7.2 Proposed new projects and updates - in vitro diagnostics |
|
|
59 | (9) |
|
7.2.1 Proposed First WHO Reference Panel for cancer mutation detection |
|
|
59 | (1) |
|
7.2.2 Proposed Third WHO International Standard for prekallikrein activator |
|
|
60 | (1) |
|
7.2.3 Proposed First WHO Reference Reagent for anti-human platelet antigen 15b |
|
|
60 | (1) |
|
7.2.4 Proposed First WHO International Standard for anti-cyclic citrullinated peptide antibodies |
|
|
61 | (1) |
|
7.2.5 Proposed Second WHO International Standard for rheumatoid factor |
|
|
62 | (1) |
|
7.2.6 Proposed Second WHO reference reagents for dengue virus subtypes 1-4 |
|
|
63 | (1) |
|
7.2.7 Proposed First WHO International Standard for cutaneous leishmaniasis; and FirstWHO Reference Panel for cutaneous leishmaniasis |
|
|
63 | (1) |
|
7.2.8 Proposed First WHO International Standard for Plasmodium vivax antigens; and First WHO Reference Reagent for anti-malaria (Plasmodium vivax) serum |
|
|
64 | (1) |
|
7.2.9 Proposed First WHO International Standard for anti-MERS-CoV serum |
|
|
65 | (1) |
|
7.2.10 Proposed First WHO International Standard for MERS-CoV RNA for NAT-based assays |
|
|
65 | (1) |
|
7.2.11 Proposed Sixth WHO International Standard for hepatitis C virus RNA for NAT-based assays |
|
|
66 | (2) |
|
8 International reference materials - vaccines and related substances |
|
|
68 | (13) |
|
8.1 WHO International Standards and Reference Reagents - vaccines and related substances |
|
|
68 | (6) |
|
8.1.1 First WHO international standards for oral poliomyelitis vaccines |
|
|
68 | (1) |
|
8.1.2 Second WHO International Standard for pertussis toxin |
|
|
69 | (1) |
|
8.1.3 First WHO international standards for Citrobacter freundii and Salmonella Typhi Vi polysaccharides |
|
|
70 | (2) |
|
8.1.4 First WHO International Standard for anti-typhoid capsular Vi polysaccharide immunoglobulin G (human) |
|
|
72 | (1) |
|
8.1.5 First WHO International Standard for antiserum to respiratory syncytial virus |
|
|
73 | (1) |
|
8.2 Proposed new projects and updates - vaccines and related substances |
|
|
74 | (7) |
|
8.2.1 Proposed First WHO Reference Panel for Vibrio cholera 01 and 0139 lipopolysaccharides |
|
|
74 | (1) |
|
8.2.2 Proposed First WHO Reference Panel for anti-Wbrio cholera 01 and 0139 lipopolysaccharide serums (rabbit) |
|
|
75 | (1) |
|
8.2.3 Proposed First WHO International Standard for Vibrio cholera vaccine (oral, inactivated) |
|
|
76 | (1) |
|
8.2.4 Proposed FirstWHO International Standard for antibody to the influenza virus haemagglutinin stem domain |
|
|
76 | (1) |
|
8.2.5 Proposed First WHO international standards for influenza virus pathogenicity for safety testing |
|
|
77 | (1) |
|
8.2.6 Proposed Third WHO International Standard for anti-rabies immunoglobulin (human) |
|
|
78 | (3) |
Annex 1 WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological substances used in medicine |
|
81 | (6) |
Annex 2 Guidelines on the quality, safety and efficacy of Ebola vaccines |
|
87 | (94) |
Annex 3 Guidelines on procedures and data requirements for changes to approved biotherapeutic products |
|
181 | (100) |
Annex 4 Technical Specifications Series (TSS) for WHO Prequalification - Diagnostic Assessment |
|
281 | (34) |
Annex 5 Technical Guidance Series (TGS) for WHO Prequalification - Diagnostic Assessment |
|
315 | (62) |
Annex 6 Biological substances: WHO International Standards, Reference Reagents and Reference Panels |
|
377 | |